Cerenome Reports Decrease in Grant Revenue and Significant Net Loss in Latest Quarter

Cerenome, Inc., formerly known as Plus Therapeutics, Inc., reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded grant revenue of $411,000 for the second quarter, a notable decrease from $1.39 million in the same period last year. For the first half of 2026, total grant revenue was $1.44 million, down from $2.45 million in the prior year. The decline in revenue is attributed to reduced funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for the development of its lead product candidate, rhenium (186Re) obisbemeda, which is aimed at treating central nervous system cancers.

Cerenome's operating expenses surged to $9.47 million for the second quarter, compared to $2.93 million in the same quarter of 2025. This increase was driven primarily by a rise in research and development costs, which reached $4.27 million, up from $1.25 million year-over-year. General and administrative expenses also rose significantly, totaling $5.20 million, compared to $1.68 million in the previous year. The company reported a net loss of $9.01 million for the second quarter, a stark contrast to a net income of $5.15 million in the same period last year, reflecting the impact of increased operational costs and reduced revenue.

In terms of strategic developments, Cerenome has made significant organizational changes, including a corporate rebranding that took effect on August 3, 2026. The company’s name change reflects its broader focus on integrated CNS oncology solutions, combining precision diagnostics, targeted therapeutics, and proprietary data analytics. Additionally, Cerenome has expanded its laboratory capabilities and signed agreements with six major payers to enhance access to its CNSide Test, a diagnostic tool for CNS cancers.

Operationally, Cerenome's total assets decreased to $14.03 million as of June 30, 2026, down from $16.33 million at the end of 2025. The company’s cash and cash equivalents also fell to $2.37 million from $4.26 million, indicating a tightening liquidity position. Current liabilities were reported at $8.57 million, down from $12.31 million, primarily due to the repayment of investor liabilities. The company’s employee headcount has increased as it expands its research and development teams to support ongoing clinical trials and product development.

Looking ahead, Cerenome anticipates continued increases in research and development expenditures as it progresses with its clinical trials, particularly the ReSPECT-LM trial for leptomeningeal metastases and the ReSPECT-PBC trial for pediatric brain cancer. The company has expressed the need to raise additional capital to fund its operations and clinical programs, raising concerns about its ability to continue as a going concern if sufficient funding is not secured.